Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 216.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,775 shares of the medical research company’s stock after buying an additional 1,899 shares during the period. E Fund Management Co. Ltd.’s holdings in Thermo Fisher Scientific were worth $1,473,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Raleigh Capital Management Inc. increased its position in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares during the period. Cedar Mountain Advisors LLC lifted its holdings in Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares during the period. Pacific Capital Wealth Advisors Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $51,000. Financial Connections Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $53,000. Finally, Operose Advisors LLC increased its position in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 75 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $4.29 during trading on Thursday, hitting $577.93. The company had a trading volume of 1,491,192 shares, compared to its average volume of 1,548,782. The stock’s 50-day moving average price is $575.75 and its 200 day moving average price is $535.39. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The firm has a market capitalization of $220.60 billion, a P/E ratio of 37.07, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,711 shares of company stock worth $21,630,972. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft increased their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. HSBC increased their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Barclays boosted their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Finally, The Goldman Sachs Group raised their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.